Funding sources Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (E0040) and 2008 grant from Department of Medical Sciences, Graduate School, Ajou University.
CLINICAL AND LABORATORY INVESTIGATIONS
Altered expression of costimulatory molecules in Behçet’s disease according to clinical activity
Article first published online: 17 MAY 2011
© 2011 The Authors. BJD © 2011 British Association of Dermatologists
British Journal of Dermatology
Volume 164, Issue 6, pages 1285–1291, June 2011
How to Cite
Sim, J.H., Park, M.J., Park, S. and Lee, E.-S. (2011), Altered expression of costimulatory molecules in Behçet’s disease according to clinical activity. British Journal of Dermatology, 164: 1285–1291. doi: 10.1111/j.1365-2133.2011.10274.x
Conflicts of interest None declared.
- Issue published online: 25 MAY 2011
- Article first published online: 17 MAY 2011
- Accepted manuscript online: 24 FEB 2011 05:42PM EST
- Accepted for publication 15 February 2011
Background The reduced expression of molecules limiting excessive immune responses has been considered a pathogenic mechanism associated with autoimmune diseases.
Objectives To understand the implications of costimulatory molecules in Behçet’s disease (BD), the expression of CTLA-4 and PD-1 on T-cell subsets and of their ligands CD80, CD86 and PD-L1 on antigen-presenting cells (APCs) was investigated.
Methods Peripheral blood mononuclear cells (PBMC) from 11 patients with active BD, eight patients with inactive BD, eight patients with recurrent aphthous ulcers and 10 healthy volunteers as healthy controls (HC) were stimulated with phorbol myristate acetate and ionomycin. The expression of costimulatory molecules was then analysed by flow cytometry. Soluble CTLA-4 (sCTLA-4) concentrations were determined by enzyme-linked immunosorbent assay and the transcript level of PD-L1 was measured by real-time polymerase chain reaction. The PD-L1 expression in skin lesions of patients with BD was evaluated by immunohistochemistry.
Results Compared with the HC group, reduced expression of CTLA-4 in CD4+ T cells after stimulation was observed in the active BD group, with no difference in the production of sCTLA-4. CD86 expression, in the resting APCs, was reduced in the active BD group compared with the HC group. PD-L1 expression in the APCs was decreased in the active BD group with or without stimulation of cells. Concordantly, the mRNA levels of PD-L1 in PBMC, and PD-L1 expression in the cutaneous lesions, were low in the active BD group.
Conclusions The results of this study suggest that altered expression of PD-L1, CTLA-4 and CD86 may be involved in the pathogenesis of BD.